Brief: Bergenbio Receives FDA Fast Track Designation For Bemcentinib In Lung Cancer
09/11/2021 13:21
Nov 9 (Reuters) - Bergenbio ASA BGBIO.OL :
* BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR
BEMCENTINIB IN
STK11-MUTATED ADVANCED/METASTATIC NON-SMALL LUNG CANCER (NSCLC)
Source text for Eikon: ID:nPn7K6N6La
Further company coverage: BGBIO.OL
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncoinvent ASA
See all newsBrief: Oncoinvent To Raise Up To NOK 140 Million In Private Placement
Brief: Oncoinvent H1 Operating Loss NOK 69 Mln
Brief: Oncoinvent Secures New Patent Expanding Protection For Radspherin
Brief: Oncoinvent's Shares To Be Consolidated In Ratio Of 100:1
Brief: Oncoinvent To Increase Share Capital In Connection With Settlement Of Underwriting Fee